Placebo in vitro [Study Per­for­mance]

posted by luvblooms  – India, 2013-06-17 09:40 (4405 d 02:04 ago) – Posting: # 10804
Views: 7,130

Dear Tina

Intended market?
Canada or EU ?

Requirements are different for different regulatory authorities.

Health Canada:Asks for full API data (batch number, manufacturing process, Structure elucidation, impurities, stability, and almost full DMF information (restricted and un restricted part: you have to get an access letter from DMF supplier if DMF has been filed in Canada), Batch number used in manufacturing the clinical lot). Apart from this HC asks for full formulation information (not limiting to manufacturing process, Method of analysis, validation protocols, dissolution details, sufficient stability data of the formulation to be dosed to define the storage period (~3 month stability), impurities profile and many more thing.

EMEA: A bit lenient. If you have a lab batch data (specially 6 month stability)with similar composition, you can go ahead with the IMPD and CTA filing.

For Placebo also you need to give all the data related to excipients under use, their grade, TSE/BSE certificate, stability data, absence of API data, manufacturing process and other process related details.

~A happy Soul~

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,692 registered users;
66 visitors (0 registered, 66 guests [including 29 identified bots]).
Forum time: 11:45 CEST (Europe/Vienna)

If I’d observed all the rules,
I’d never have got anywhere.    Marilyn Monroe

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5